Article
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
BMC medicine - 28 Apr 2023
Hu Xingsheng, Zhang Shucai, Ma Zhiyong, Feng Jifeng, Wu Lin, Lv Dongqing, Zhou Jianying, Zhang Xiaodong, Liu Li, Yu Qitao, Liao Wangjun, Zhang Yiping, Wang Xiang, Cheng Ying, Niu Hongrui, Wang Ziping, Wang Dong, Huang Cheng, Liu Chunling, Zhao Hui, Feng Jian, Li Jingzhang, Ying Kejing, Yang Nong, Qin Shukui, Hu Jie, Liu Fei, Jiang Yong, Ge Nan, Shi Yuankai
Abstract excerpt
BACKGROUND: Furmonertinib (AST2818) is a brain penetrant pan-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both EGFR sensitizing mutations and T790M mutation. We report the pooled central nervous system (CNS) efficacy data of furmonertinib in patients with EGFR T790M mutated non-small cell lung cancer (NSCLC) from two phase 2 studies. METHODS: This was a pooled, post-hoc...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.